BioSpace News Archive

Aileron Therapeutics today reported financial results and business highlights for the third quarter ended September 30, 2021.

BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), today announced that management will present at and host one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021.

Chimerix,a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced that Mike Sherman, Chief Executive Officer of Chimerix, will participate in a pre-recorded presentation at the Jefferies London Healthcare Conference that will be made available on Thursday, November 18, 2021 at 3:00 a.m. ET.

Cue Biopharma, Inc. (Nasdaq: CUE), announced today the presentation of interim data further demonstrating the tolerability and antitumor activity potential of CUE-101 as a monotherapy as part of the Company’s ongoing clinical trial for the treatment of recurrent/metastatic HPV+ head and neck cancer in a poster at the Society for Immunotherapy of Cancer’s 36th Annual Meeting.

Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported preclinical data from the company’s newly selected core inhibitor candidate, ABI-4334 (4334), and clinical results from the Phase 1a study of ABI-H3733 (3733) in healthy volunteers at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting™

Prelude Therapeutics Inc., a clinical-stage precision oncology company, announced its financial results for the third quarter ended September 30, 2021 and provided an update on recent clinical and development pipeline progress.

Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced new clinical data on sotigalimab in three poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, being held both virtually and in Washington, D.C., November 10-14, 2021.

Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the Company plans to participate in the upcoming 2021 Stifel Virtual Healthcare Conference.

Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced results from ongoing Phase 1 and Phase 1b/2a clinical trials of VTP-300, an immunotherapy candidate in development for the treatment of CHB infection.